Sign In
Buy AGESY
Ageas SA (ADR) Earnings Calls
| Release date | Feb 10, 2026 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Expected change | +/- 1.06% |
| Release date | Aug 25, 2025 |
| EPS estimate | $4.26 |
| EPS actual | $1.83 |
| EPS Surprise | -57.04% |
| Revenue estimate | - |
| Revenue actual | 2.206B |
| Release date | May 23, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Feb 27, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for Ageas SA (ADR)
Below you can see how AGESY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 27, 2025 |
| Price on release | $55.48 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Feb 21, 2025 | $53.28 |
| Feb 24, 2025 | $53.69 |
| Feb 25, 2025 | $54.45 |
| Feb 26, 2025 | $55.58 |
| Feb 27, 2025 | $55.48 |
| Feb 28, 2025 | $54.11 |
| Mar 03, 2025 | $55.49 |
| Mar 04, 2025 | $57.13 |
| Mar 05, 2025 | $57.39 |
| 4 days before | 4.13% |
| 4 days after | 3.44% |
| On release day | -1.71% |
| Change in period | 7.71% |
| Release date | May 23, 2025 |
| Price on release | $64.85 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 19, 2025 | $64.59 |
| May 20, 2025 | $65.22 |
| May 21, 2025 | $65.86 |
| May 22, 2025 | $65.74 |
| May 23, 2025 | $64.85 |
| May 27, 2025 | $65.19 |
| May 28, 2025 | $64.78 |
| May 29, 2025 | $65.42 |
| May 30, 2025 | $65.35 |
| 4 days before | 0.403% |
| 4 days after | 0.771% |
| On release day | 0.200% |
| Change in period | 1.18% |
| Release date | Aug 25, 2025 |
| Price on release | $72.42 |
| EPS estimate | $4.26 |
| EPS actual | $1.83 |
| EPS surprise | -57.04% |
| Date | Price |
|---|---|
| Aug 19, 2025 | $72.78 |
| Aug 20, 2025 | $73.45 |
| Aug 21, 2025 | $73.01 |
| Aug 22, 2025 | $73.43 |
| Aug 25, 2025 | $72.42 |
| Aug 26, 2025 | $72.00 |
| Aug 27, 2025 | $71.13 |
| Aug 28, 2025 | $70.96 |
| Aug 29, 2025 | $70.55 |
| 4 days before | -0.495% |
| 4 days after | -2.58% |
| On release day | -0.580% |
| Change in period | -3.06% |
| Release date | Feb 10, 2026 |
| Price on release | - |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Nov 11, 2025 | $67.54 |
| Nov 12, 2025 | $67.67 |
| Nov 13, 2025 | $68.16 |
| Nov 14, 2025 | $67.91 |
| Nov 17, 2025 | $67.74 |
Ageas SA (ADR) Earnings Call Transcript Summary of Q2 2025
Ageas reported a strong start to Elevate27 in H1 2025 with 4% inflows (Life +6%) and a robust net operating result of EUR 734m (EUR 665m adjusted for China tax and favorable weather). Non-Life delivered an excellent combined ratio of 92.1%; Life showed broad commercial momentum (Belgium +10% inflows) and a deliberate product mix shift in China toward participating products. Management raised full-year net operating result guidance to EUR 1.30–1.35bn (including esure) and increased Elevate27 financial targets: holding free cash flow >EUR 2.3bn and shareholder remuneration >EUR 2bn, while maintaining the EPS growth target of 6–8% (despite ~11m new shares). Operational capital generation was strong at EUR 1.1bn and holding cash upstream guidance was upgraded to EUR 940m for 2025 (EUR 725m already received). Esure acquisition approvals are progressing and management still expects closing by end-September; however, full financial benefits and synergies are expected only from 2028, with near-term integration costs and ~EUR 1bn of financing already factored in. Key risks/assumptions flagged: potential exceptional weather, volatile financial markets, and an uncertain full-year effective tax rate in China (guidance assumes reversion to 25% corporate tax).
